ClinicalTrials.gg
CompletedNCT05600114Updated Nov 21, 2024

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

A Phase 2 interventional study of Cannabidiol oral solution and Cannabidiol oral solution in Social Anxiety Disorder, sponsored by EmpowerPharm Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by EmpowerPharm Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Nov 2024.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Phobia, Social with a site in United States — 23 open to participants now, 29 under way, 1 of them phase 3. Phobia, Social · United States.

Enrollment
25th of 178
239 · median 64
Started
2022
with 15 others
Phase 2
25 of 187
2 open now
Registered
147th of 187
by date

Among the 187 studies in Phobia, Social with a site in United States, this one is the 25th largest by enrollment of the 178 interventional ones that give a count, is one of 16 that started in 2022, is one of 25 in phase 2, and was the 147th registered.

Phobia, Social

368 studies on the registry are indexed under Phobia, Social; 59 are open to participants now.

Browse Phobia, Social studies →

Open to participants now

23 of the 187 studies in Phobia, Social with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Phobia, Social studies recruiting now, 10 (22%) set no upper age limit and 34 (74%) stop at 75 or younger; 14 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Phobia, Social with a site in United States, or all of them as a file.
02

Study summary

A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).

03

Conditions studied

  • Social Anxiety Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically predominant diagnosis of , Fifth Edition (DSM-5) SAD
  • LSAS score of 70 or higher
  • Females of must test negative for pregnancy and agree to use a reliable method. Male subjects must also agree to use highly effective methods of contraception.
  • Read, understand, and sign the form.
  • No significant physical health abnormalities based on physical exam, and laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • Other current psychiatric disorder as the clinically predominant diagnosis.
  • Lifetime diagnosis of schizophrenia or any other psychosis, MDD with psychotic features, intellectual disability, autism spectrum disorders, bipolar disorder type 1, and cannabis use disorder
  • Previous 6 months diagnosis of Post-traumatic stress disorder, obsessive compulsive disorder, moderate to severe alcohol use disorder, and substance abuse disorder (except tobacco use disorder or mild alcohol use disorder)
  • Severe MDD
  • Use of oral psychoactive medications or beta adrenergic antagonists in the past 4 weeks, or depot neuroleptics within 12 weeks
  • Electroconvulsive therapy within 6 months, psychotherapy or transcranial magnetic stimulation within 3 months
  • abnormality or clinically significant unstable medical condition
  • Impaired liver function
  • Significant risk of suicide or homicide
  • Pregnancy/lactation
  • Sensitivity to CBD or
  • Current cannabis use; past frequent cannabis use
  • Illegal drug use
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    Cannabidiol (CBD) Oral Solution 300 mg/day

    Drug: Cannabidiol oral solution

  • Experimental
    Cannabidiol (CBD) Oral Solution 600 mg/day

    Drug: Cannabidiol oral solution

  • Placebo comparator
    Placebo Oral Solution

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline to endpoint in the Liebowitz Social Anxiety Scale (LSAS)

    Time frame: 10 weeks

07

Study locations

17 sites
  • EPI-CBD-001 Site
    Encino, California 91316, United States
  • EPI-CBD-001 Site
    Lemon Grove, California 91945, United States
  • EPI-CBD-001 Site
    Los Alamitos, California 90720, United States
  • EPI-CBD-001-Site
    Oceanside, California 92056, United States
  • EPI-CBD-001 site
    San Jose, California 95124, United States
  • EPI-CBD-001 Site
    Jacksonville, Florida 32256, United States
  • EPI-CBD-001 Site
    Lauderhill, Florida 33319, United States
  • EPI-CBD-001 Site
    Maitland, Florida 32751, United States
  • EPI-CBD-001 Site
    Orlando, Florida 32801, United States
  • EPI-CBD-001 Site
    Chicago, Illinois 60640, United States
  • EPI-CBD-001 Site
    Cedarhurst, New York 11516, United States
  • EPI-CBD-001-Site
    New York, New York 10036, United States
  • EPI-CBD-001-Site
    Rochester, New York 10036, United States
  • EPI-CBD-001 Site
    Oklahoma City, Oklahoma 73106, United States
  • EPI-CBD-001 Site
    Portland, Oregon 97210, United States
  • EPI-CBD-001 site
    Wichita Falls, Texas 76309, United States
  • EPI-CBD-001 Site
    Bellevue, Washington 98007, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Dec 2023, 13 months.

Of 15 phase 2 interventional studies under Phobia, Social, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Oct 31, 2022
StartActual
Oct 27, 2022
Primary completionActual
Dec 13, 2023
CompletionActual
Dec 13, 2023
Results delay requested
Nov 15, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05600114
Lead sponsor
EmpowerPharm Inc.
Responsible party
Sponsor
First posted
Oct 31, 2022
Start date
Oct 27, 2022
Primary completion
Dec 13, 2023
Completion
Dec 13, 2023
Last update
Nov 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion